Safety pharmacology of therapeutic agents: Evaluation strategies and clinical relevance

Introduction

Safety pharmacology is an important component of non-clinical drug development that evaluates the potential undesirable pharmacodynamic effects of therapeutic agents on vital physiological systems before human clinical studies (Dean and Olson, 1993). Its primary goal is to identify adverse functional effects that may occur at or above the expected therapeutic dose, thereby ensuring patient safety. Unlike primary pharmacology, which studies the intended therapeutic effects of a drug, safety pharmacology focuses on unintended effects that may affect critical organ systems. Early detection of such effects helps researchers make informed decisions during drug development and minimizes the risk of unexpected adverse reactions in clinical trials (Hamdam et al., 2013). Modern safety pharmacology integrates pharmacodynamic and pharmacokinetic data to assess drug-induced changes, particularly in the cardiovascular, respiratory, and central nervous systems. Advances in telemetry, in vitro screening, and computational modeling have further improved the prediction of clinically significant adverse effects, strengthening its role in the risk-benefit assessment of new therapeutic agents (Pugsley et al., 2008) [8,15,30] .

In contrast to conventional toxicology, which mainly examines tissue damage and pathological changes, safety pharmacology is concerned with functional alterations that may occur even in the absence of visible structural abnormalities. These changes can affect critical organ systems and may result in serious clinical consequences if not identified during preclinical studies. The development of safety pharmacology has been driven by scientific advances in pharmacology, increasing regulatory expectations, and lessons learned from adverse drug reactions observed in clinical practice. Information obtained from safety pharmacology studies supports regulatory decisions and helps establish appropriate safety monitoring during clinical trials. Collaboration among researchers, pharmaceutical companies, contract research organizations, and regulatory authorities has improved testing methods and enhanced the reliability of safety assessments. Furthermore, the continuous evaluation and publication of research findings have strengthened the predictive value of preclinical safety models (Khakoo et al., 2008). With rapid technological progress and the development of novel therapeutic agents, safety pharmacology continues to play a vital role in modern drug development by improving the early identification of potential safety concerns and supporting safer clinical use of pharmaceuticals (Bass et al., 2004) [20,5] .

Origin of Safety Pharmacology

The foundation of safety pharmacology arose from the recognition that pharmaceutical compounds can adversely influence organ function even in the absence of detectable structural damage. Traditional toxicological studies are effective in identifying morphological lesions and tissue injury; however, they may fail to reveal functional disturbances affecting critical physiological systems. This limitation highlighted the need for a specialized discipline dedicated to the evaluation of drug-induced functional effects (Marshall, 2001). Among the various physiological systems, the cardiovascular, respiratory, and central nervous systems have been identified as the most vulnerable to clinically significant adverse pharmacodynamic effects. Drug-induced arrhythmias, alterations in blood pressure, bronchoconstriction, respiratory depression, seizures, and neurological dysfunction are examples of adverse responses that may rapidly progress to medical emergencies if not detected during preclinical evaluation. As pharmaceutical innovation expanded and increasingly complex therapeutic molecules entered development pipelines, regulatory authorities recognized the need for standardized safety assessment strategies. This led to the incorporation of dedicated safety pharmacology studies into international regulatory frameworks, ensuring that potential risks to essential physiological functions are identified and managed before clinical application. Today, safety pharmacology represents an indispensable component of non-clinical drug development and plays a critical role in protecting clinical trial participants and future patients by facilitating early risk identification and informed decision-making (Kinter et al.,2004) [2] .

Objectives of Safety Pharmacology Studies

Safety pharmacology studies are conducted to identify and characterize undesirable pharmacodynamic effects that may compromise the safety of a pharmaceutical compound during clinical use. These investigations provide essential information regarding the impact of a drug on major By achieving these objectives, safety pharmacology plays a crucial role in minimizing the likelihood of unexpected adverse events during clinical trials and contributes significantly to the development of safer and more effective medicines (Anon, 2000) [2] .

Principles of Safety Pharmacology

Safety pharmacology is founded on scientific principles aimed at ensuring that new therapeutic agents do not produce unacceptable adverse effects on essential physiological functions. These principles guide the design, conduct, interpretation, and regulatory application of safety studies throughout the drug development process. The major principles of safety pharmacology include:

• Application of scientifically valid and reproducible methodologies. Adherence to these principles ensures that safety pharmacology studies provide meaningful information for identifying potential hazards and contribute to the development of safer and more effective therapeutic agents (Andrade et al., 2016) [1] .

Selection, Designing and Program of Safety Pharmacology Studies

The planning and design of safety pharmacology studies are essential for accurately evaluating the potential adverse effects of new drug candidates. Study protocols should consider the physicochemical properties, pharmacological profile, and intended clinical use of the compound to ensure meaningful and reliable safety data. The therapeutic class and mechanism of action of a drug are important factors in study design, as compounds within the same class may exhibit similar safety concerns. Therefore, known class-related adverse effects should be considered when selecting appropriate study endpoints. Safety assessments should also address unintended or off-target effects that are unrelated to the primary pharmacological action of the drug. Such interactions may produce unexpected physiological responses that can only be detected through dedicated safety pharmacology testing. Data from receptor binding studies, enzyme assays, molecular screening, and previous pharmacological, toxicological, and pharmacokinetic investigations provide valuable information for identifying potential safety risks. Integrating these findings helps in designing focused and efficient safety pharmacology studies and supports better prediction of human safety profiles.

The design of a safety pharmacology program generally considers the following factors:

1. Adverse effects associated with the therapeutic mechanism of the test substance. A well-structured safety pharmacology program allows for the early identification of potential hazards, supports regulatory submissions, and contributes significantly to the development of safer medicines with improved clinical outcomes.

Safety Pharmacology Core Battery

The core battery of safety pharmacology studies represents the fundamental set of investigations performed to evaluate the effects of a pharmaceutical compound on vital physiological functions that are essential for life. Regulatory authorities recommend that these studies be completed before the initiation of human clinical trials to ensure an adequate assessment of potential safety risks.

The principal objective of the core battery is to detect adverse pharmacodynamic effects on the cardiovascular, respiratory, and central nervous systems, as these systems are most frequently associated with serious clinical complications resulting from drug administration. International regulatory guidelines, including ICH S7A and S7B, recognize these organ systems as critical components of preclinical safety assessment.

Central Nervous System Evaluation

Assessment of central nervous system function aims to identify drug-induced alterations in neurological and behavioral activities. The parameters commonly evaluated include spontaneous locomotor activity, posture, coordination, reflex responses, sensory perception, and body temperature regulation. Behavioral observation methods such as the Functional Observation Battery (FOB), modified Irwin test, and related neurobehavioral assessments are widely employed to detect changes in neurological status and functional performance (Lindgren et al., 2008) [23] .

Cardiovascular System Evaluation

Cardiovascular safety assessment is considered one of the most important components of safety pharmacology because cardiac adverse events can have serious or fatal consequences. Studies typically evaluate heart rate, arterial blood pressure, and electrocardiographic parameters to identify potential disturbances in cardiac function. Additional investigations may include assessment of cardiac conduction, ventricular repolarization, and arrhythmogenic potential using in vivo, in vitro, or ex vivo models. Particular attention is given to QT interval prolongation and abnormalities in cardiac electrophysiology that may predispose individuals to life-threatening arrhythmias (Laverty et al., 2011) [22] .

Respiratory System Evaluation

Respiratory safety studies are conducted to determine whether a test substance interferes with normal pulmonary function. Parameters such as respiratory rate, tidal volume, minute ventilation, and oxygen saturation are commonly measured to evaluate respiratory performance. Since simple clinical observation may fail to detect subtle respiratory impairment, quantitative methods and specialized instrumentation are generally required to provide reliable and reproducible results (Authier et al., 2008) [3] .

Importance of the Core Battery

The core battery serves as the foundation of most safety pharmacology programs and fulfills the major regulatory requirements for non-clinical safety evaluation. Depending on the pharmacological profile of the investigational compound, these studies may be supplemented with additional assessments targeting other organ systems or specific safety concerns. Integration of cardiovascular and respiratory assessments in selected non-rodent species can improve efficiency, reduce costs, and optimize resource utilization without compromising scientific quality.

Supplemental Studies

In addition to the core battery investigations, supplemental safety pharmacology studies are performed when the pharmacological characteristics of a test compound or findings from previous studies indicate the possibility of adverse effects on additional organ systems. These investigations provide a more comprehensive evaluation of drug safety and assist in identifying organ-specific toxicities that may not be detected through routine assessments of cardiovascular, respiratory, and central nervous system functions.

Renal and Urinary System Assessment

Evaluation of renal function is important when a test substance is suspected to influence fluid balance, electrolyte homeostasis, or urinary excretion mechanisms. Parameters commonly monitored include urine volume, specific gravity, osmolality, urinary pH, electrolyte concentrations, protein excretion, and urinary sediment examination. Biochemical markers such as blood urea nitrogen, serum creatinine, and plasma protein concentrations are also useful indicators of renal function and potential nephrotoxicity.

Autonomic Nervous System Assessment

Supplemental investigations of the autonomic nervous system may be necessary for compounds capable of interacting with autonomic receptors or neural pathways. Such studies can include receptor-binding assays, pharmacological responses to agonists and antagonists, direct nerve stimulation experiments, baroreceptor reflex evaluations, and measurements of heart rate variability. These assessments contribute to understanding the effects of a compound on sympathetic and parasympathetic regulation.

Gastrointestinal System Assessment

The gastrointestinal tract may require detailed evaluation when there is concern regarding drug-induced alterations in digestive function or mucosal integrity. Parameters such as gastric acid secretion, intestinal transit time, bile production, gastrointestinal motility, and gastric pH can be measured using appropriate experimental models. In vitro studies involving isolated intestinal tissues may also be employed to investigate effects on smooth muscle contractility and secretory activity (Harrison et al., 2004) [16] .

Evaluation of Other Organ Systems

Depending on the pharmacological profile and mechanism of action of the investigational product, additional organ systems may require assessment. Studies may be designed to investigate potential effects on skeletal muscle function, endocrine activity, immune responses, reproductive performance, or dependence liability. The decision to conduct such investigations should be based on scientific evidence and specific safety concerns identified during earlier stages of development (Fuchs and Hewitt, 2011) [11] .

Significance of Supplemental Studies

Supplemental safety pharmacology studies enhance the understanding of the overall safety profile of a pharmaceutical compound by addressing organ systems beyond those included in the core battery. These studies provide valuable information for regulatory submissions, improve risk assessment, and facilitate the development of appropriate clinical monitoring strategies for future human studies.

General Considerations for Selection of Test Systems

The selection of an appropriate test system is a critical step in safety pharmacology studies because the reliability and relevance of the generated data largely depend on the suitability of the experimental model. The chosen system should be capable of producing scientifically valid, reproducible, and clinically meaningful information regarding the safety profile of the investigational compound.

In addition, the sensitivity, specificity, and reproducibility of the selected model should be evaluated before its application in regulatory studies. Availability of historical control data and previous experience with the selected species also contribute to improving the interpretation and reliability of study findings (Guideline, I. C. H. 2001) [14] .

Use of In vivo and In vitro Test Systems

Safety pharmacology studies employ both in vivo and in vitro approaches to evaluate the functional safety of investigational drugs.

In vivo Studies

In vivo studies are widely used because they allow the assessment of multiple physiological systems under conditions that closely mimic clinical situations. These studies provide information on systemic drug effects, organ interactions, and time-dependent responses. Whenever possible, conscious and minimally restrained animals are preferred to avoid physiological changes caused by anesthesia or stress. Modern telemetry techniques enable continuous monitoring of cardiovascular, respiratory, and neurological functions. Ethical considerations and animal welfare guidelines must be strictly followed during these investigations.

In vitro Studies

In vitro methods complement animal studies by evaluating target-specific and mechanistic effects using isolated tissues, cultured cells, receptors, ion channels, enzymes, and other experimental models. These techniques offer advantages such as better experimental control, lower costs, and reduced use of laboratory animals. They are particularly useful for early safety screening and mechanistic investigations.

Importance of Test System Selection

The selection of appropriate test systems is critical for accurately predicting human safety risks. A combination of in vivo and in vitro methods provides comprehensive information and enhances the reliability of safety pharmacology assessments.

Dose Levels or Concentration of Test Substance

In vivo Studies Dose selection should be based on available pharmacological, toxicological, and pharmacokinetic data. Safety pharmacology studies are designed to establish dose-response relationships and evaluate the onset, severity, duration, and reversibility of adverse effects. The selected doses should include the expected therapeutic exposure and higher exposure levels to determine safety margins. Excessive toxicity that may interfere with data interpretation should be avoided, and species-specific differences in drug responses should be considered (Bowes et al., 2012) [7] .

In vitro Studies

In in vitro investigations, an appropriate concentration range is selected to identify biological effects of the test compound. Factors such as solubility, chemical stability, protein binding, and assay limitations influence concentration selection. When no pharmacological response is observed, the concentration range used should be scientifically justified (Whitebread et al., 2005) [33] .

Importance of Dose Selection

Careful selection of dose levels and concentrations improves the accuracy of risk assessment and assists in defining therapeutic safety margins. Appropriate dose-ranging strategies also facilitate regulatory evaluation and contribute to the identification of clinically relevant adverse effects during the early stages of drug development (Whitebread et al., 2005) [33] .

Duration of Studies

The duration of safety pharmacology studies should be selected according to the pharmacological characteristics of the investigational compound and the objectives of the assessment. In most situations, these studies are performed following a single administration of the test substance to evaluate acute functional effects on major physiological systems.

However, certain pharmaceutical agents may produce adverse responses only after repeated exposure or prolonged treatment. In such circumstances, the study duration should be extended to adequately characterize delayed or cumulative pharmacodynamic effects. Information obtained from repeatdose toxicity studies, pharmacokinetic investigations, and previous clinical observations can assist in determining the appropriate duration of evaluation. The time course of adverse effects, including their onset, severity, persistence, and reversibility, should be carefully documented whenever possible. Such information contributes significantly to the understanding of drug safety and facilitates the establishment of appropriate monitoring strategies during clinical development. Consequently, the duration of safety pharmacology studies should be scientifically justified and tailored to the expected clinical use, dosing schedule, and pharmacological properties of the candidate drug. (Jarvis et al., 2010) [19] .

Studies on Metabolites, Isomers and Finished Products

Safety pharmacology assessment should not be restricted solely to the parent compound, particularly when metabolites contribute substantially to the pharmacological or toxicological activity of the drug. Major metabolites that are expected to achieve clinically relevant systemic exposure in humans should be considered during the safety evaluation process.

In many instances, studies involving the parent compound in laboratory animals provide sufficient information regarding metabolite safety. However, when important human metabolites are absent or produced only in small quantities in experimental species, separate investigations may be necessary to determine their potential effects on physiological functions. Active metabolites that significantly contribute to therapeutic efficacy or adverse reactions deserve particular attention because they may influence the overall safety profile of the medicinal product. Depending on practical considerations and scientific requirements, these evaluations may be conducted using either in vivo or in vitro methodologies. For pharmaceutical products containing stereoisomeric mixtures, assessment of individual isomers may be necessary because different isomers can exhibit distinct pharmacodynamic and pharmacokinetic characteristics. Evaluation of each isomer helps identify possible differences in efficacy, toxicity, and safety margins. Safety pharmacology studies involving finished pharmaceutical formulations are generally required only when the formulation significantly alters the absorption, distribution, metabolism, excretion, or pharmacological activity of the active ingredient. Such situations may occur with the use of specialized delivery systems, absorption enhancers, liposomal preparations, or formulation changes capable of modifying drug exposure. Comprehensive assessment of metabolites, isomers, and finished formulations improves the accuracy of risk evaluation and contributes to the development of safer and more effective therapeutic products (Gao, at el., 2005) [13] .

Goals of Safety Pharmacology Assessment

The primary purpose of safety pharmacology assessment is to identify potential safety concerns associated with an investigational medicinal product at the earliest possible stage of development. Early recognition of adverse pharmacodynamic effects enables pharmaceutical companies and researchers to make informed decisions regarding the future of a drug candidate and helps prevent unnecessary investment in compounds with unacceptable safety profiles. One of the major objectives of these studies is to support the selection of compounds that possess an acceptable balance between therapeutic efficacy and potential risk. Candidate molecules demonstrating significant functional toxicity can be modified, replaced by structurally related compounds, or withdrawn from further development before entering costly clinical trials. Safety pharmacology assessments also contribute to the optimization of drug development strategies by providing information regarding target organ toxicity, dose limitations, and safety margins. Such data are valuable for designing subsequent toxicological studies and establishing appropriate clinical monitoring procedures. The definitive evaluation of clinical safety generally requires extensive post-marketing surveillance and analysis of data obtained from large patient populations exposed to the therapeutic agent under real-world conditions. Therefore, the principal role of safety pharmacology is not to declare a compound absolutely safe but rather to identify and minimize foreseeable risks before human exposure and to facilitate evidence-based decision-making throughout the drug development process.

Conditions Under Which Safety Pharmacology Studies

May Not Be Necessary; In certain circumstances, dedicated safety pharmacology investigations may be reduced or omitted when sufficient scientific evidence indicates a low probability of clinically relevant adverse effects. For locally administered products such as dermatological or ophthalmic preparations, separate safety pharmacology studies may not be required if systemic absorption is minimal and the pharmacological characteristics of the active substance are already well established. Similarly, cytotoxic agents intended for the treatment of advanced malignancies may not always require extensive safety pharmacology evaluation prior to first administration in humans, particularly when the expected therapeutic benefit outweighs potential risks. However, compounds possessing novel mechanisms of action may still require additional investigation to identify previously unrecognized safety concerns. Biotechnologyderived medicinal products that act through highly selective receptor interactions often permit incorporation of safety pharmacology endpoints into toxicological or pharmacodynamic studies, thereby reducing the need for separate investigations. Conversely, products with complex or poorly characterized mechanisms of action may require a more comprehensive safety evaluation. Additional exemptions may be considered for modified formulations, salts, or derivatives of previously characterized compounds when available evidence demonstrates comparable pharmacokinetic behaviour, pharmacodynamic activity, and safety profiles. The decision to waive or reduce safety pharmacology testing should always be based on sound scientific justification and should comply with applicable regulatory requirements to ensure adequate protection of clinical trial participants and future patients.

Preclinical Safety Pharmacology Models Require Better Validation:

The predictive value of preclinical safety pharmacology models depends largely on their ability to accurately reproduce adverse effects that may occur in humans. Therefore, continuous validation of these experimental models is essential to improve their reliability and usefulness during drug development. Validation involves comparing responses obtained from experimental systems with known clinical outcomes associated with established positive and negative control compounds. Such comparisons help determine the sensitivity, specificity, and predictive accuracy of the model for identifying particular safety liabilities. However, validation remains challenging for adverse events that occur infrequently in humans or for reactions whose mechanisms are not completely understood. Similarly, assessment of biological products and highly specific therapeutic agents may be complicated by species differences and immunogenic responses in laboratory animals. In situations where fully validated models are unavailable, investigators often rely on surrogate biomarkers and indirect indicators of toxicity. Although these approaches provide useful information, interpretation of surrogate endpoints may involve a degree of uncertainty and subjective judgment. Consequently, continuous refinement of experimental methods, incorporation of emerging technologies, and development of improved translational models are essential to enhance the predictive capability of preclinical safety pharmacology investigations (Denayer et al., 2014) [9] .

Application of Good Laboratory Practice (GLP):

Good Laboratory Practice represents an internationally accepted quality assurance system designed to ensure the integrity, consistency, and traceability of non-clinical safety studies. Compliance with GLP principles enhances confidence in study findings and supports their acceptance by regulatory authorities worldwide. The core battery of safety pharmacology studies is generally expected to be performed in accordance with GLP requirements whenever practical and feasible. Adherence to standardized operating procedures, proper documentation, calibration of equipment, and systematic archiving of study records contribute significantly to maintaining data quality and reproducibility. Certain exploratory, mechanistic, or supplemental investigations may not always be conducted under full GLP compliance because of technical or logistical limitations. Nevertheless, even in these situations, investigators should maintain high standards of scientific rigor and ensure adequate documentation to permit reconstruction and verification of study findings. When studies or specific components are performed outside formal GLP conditions, the reasons for non-compliance and their potential impact on data interpretation should be clearly documented and scientifically justified. The implementation of GLP principles strengthens the credibility of safety pharmacology data and facilitates regulatory review during the drug approval process. (Lumley,1994) [24] .

Future of Safety Pharmacology

The field of safety pharmacology continues to evolve in response to rapid advances in biomedical science, molecular pharmacology, and pharmaceutical technology. Emerging therapeutic modalities such as monoclonal antibodies, gene therapies, RNA-based medicines, and cell-based treatments are creating new challenges and opportunities for safety assessment. Technological innovations including highthroughput screening, computational toxicology, artificial intelligence, systems pharmacology, and advanced in vitro models are improving the ability to predict adverse drug reactions at earlier stages of development. These approaches have the potential to reduce development costs, improve translational accuracy, and decrease reliance on experimental animals. Modern electrophysiological methods have significantly improved the assessment of cardiac safety, while telemetry systems allow continuous monitoring of physiological parameters in conscious animals under minimally stressful conditions (Azer et al., 2021). Advances in organ-on-chip technologies and human-derived cellular models may further enhance the relevance of preclinical investigations to human clinical outcomes (Redfern et al., 2003). As scientific understanding and regulatory expectations continue to develop, safety pharmacology will remain an essential discipline for ensuring the safe and effective introduction of novel therapeutic agents into clinical practice [4,31] .

Conclusion

Safety pharmacology occupies a central position in the nonclinical evaluation of pharmaceutical products by identifying potential adverse effects on vital physiological systems before human exposure occurs. These studies provide information that complements traditional toxicological investigations and improve the understanding of functional safety risks associated with new therapeutic agents. The assessment of cardiovascular, respiratory, and central nervous system functions through core battery studies forms the foundation of modern safety pharmacology programs, while supplemental investigations allow more detailed evaluation of additional organ systems when scientifically justified. Advances in molecular biology, electrophysiology, telemetry, computational modeling, and alternative experimental methods are continually improving the predictive value of safety assessments and facilitating more efficient drug development strategies. Although no preclinical model can completely predict human responses, safety pharmacology plays a crucial role in reducing uncertainty, supporting regulatory decision-making, and improving patient safety. Continued innovation and refinement of experimental methodologies will further strengthen the contribution of safety pharmacology to the discovery and development of safer and more effective medicines.

References

1. Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, Calixto JB. Non-clinical studies in the process of new drug development-Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res. 2016;49(1):2345-2367.
2. International Council for Harmonisation (ICH). ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals. London; 2000.
3. Authier S, Legaspi M, Gauvin D, Chaurand F, Fournier S, Troncy E. Validation of respiratory safety pharmacology models: Conscious and anesthetized beagle dogs. J Pharmacol Toxicol Methods. 2008;57(1):52-60.
4. Azer K, Kaddi CD, Barrett JS, Bai JP, McQuade ST, Merrill NJ, Baliga NS. History and future perspectives on the discipline of quantitative systems pharmacology modeling and its applications. Front Physiol. 2021;12:6379.
5. Bass A, Kinter L, Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods. 2004;49(3):145-151.
6. Biasiucci A, Franceschiello B, Murray MM. Electroencephalography. Curr Biol. 2019;29(3):R80R85.
7. Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, Whitebread S. Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012;11(12):909-922.
8. Dean JH, Olson HM. The integration of investigative toxicology in the drug discovery process. Biol Cell. 1993;77(1):3-8.
9. Denayer T, Stöhr T, Van Roy M. Animal models in translational medicine: Validation and prediction. New Horiz Transl Med. 2014;2(1):5-11.
10. U.S. Food and Drug Administration. ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals. Silver Spring (MD): FDA; 2001.
11. Fuchs TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity: An overview for applied toxicology. Mol Diagn Ther. 2011;15(2):615-631.
12. Fung M, Anna K, Hsiao-Hui K, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets. Drug Inf J. 2001;35(4):293-317.
13. Gao J, Kashfi K, Rigas B. In vitro metabolism of nitric oxide-donating aspirin: The effect of positional isomerism. J Pharmacol Exp Ther. 2005;312(3):989997.
14. International Council for Harmonisation (ICH). Safety pharmacology studies for human pharmaceuticals S7A. Fed Regist. 2001;66(30):36791-36792.
15. Hamdam J, Sethu S, Smith T, Alfirevic A, Alhaidari M, Atkinson J, et al. Safety pharmacology-Current and emerging concepts. Toxicol Appl Pharmacol. 2013;273(2):229-241.
16. Harrison AP, Erlwanger KH, Elbrond VS, Andersen NK, Unmack MA. Gastrointestinal tract models and techniques for use in safety pharmacology. J Pharmacol Toxicol Methods. 2004;49(2):187-199.
17. International Council for Harmonisation (ICH). ICH Harmonised Tripartite Guideline M3: Timing of Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. 1997.
18. International Council for Harmonisation (ICH). ICH Harmonised Tripartite Guideline S6: Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals. 1997.
19. Jarvis P, Srivastav S, Vogelwedde E, Stewart J, Mitchard T, Weinbauer G. The cynomolgus monkey as a model for developmental toxicity studies: Variability of pregnancy losses, statistical power estimates, and group size considerations. Birth Defects Res A Clin Mol Teratol. 2010;89(3):175-187.
20. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C. Heart failure associated with sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;113(9):2500-2508.
21. Kinter LB, Valentin JP. Safety pharmacology and risk assessment. Fundam Clin Pharmacol. 2002;16(3):175182.
22. Laverty HG, Benson C, Cartwright EJ, Cross MJ, Garland C, Hammond T, Valentin JP. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011;163(4):675-693.
23. Lindgren S, Bass AS, Briscoe R, Bruse K, Friedrichs GS, Kallman MJ, Markgraf C, Patmore L, Pugsley MK. Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods. 2008;58(2):99-109.
24. Lumley CE. General pharmacology, the international regulatory environment, and harmonization of guidelines. Drug Dev Res. 1994;32(4):223-232.
25. Marshall E. Volunteer's death prompts review. Science. 2001;292(5523):2225-2227.
26. Marshall E. Procedures faulted in fatal asthma trial. Science. 2001;293(5530):405-406.
27. Marshall J, Kushnir Y, Battisti D, Chang P, Czaja A, Dickson R, Visbeck M. North Atlantic climate variability: Phenomena, impacts and mechanisms. Int J Climatol. 2001;21(15):1863-1898.
28. Mattsson JL, Spencer PJ, Albee RR. A performance standard for clinical and functional observational battery examinations of rats. J Am Coll Toxicol. 1996;15(3):239-254.
29. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264(21):2788-2790.